Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 60/100

Failure Rate

14.3%

1 terminated/withdrawn out of 7 trials

Success Rate

66.7%

-19.8% vs industry average

Late-Stage Pipeline

14%

1 trials in Phase 3/4

Results Transparency

0 of 2 completed trials have results

Key Signals

Enrollment Performance

Analytics

N/A

2(50.0%)

Phase 3

1(25.0%)

Phase 1

1(25.0%)

4Total

N/A(2)

Phase 3(1)

Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials

NCT04632251Not ApplicableUnknown

Evaluation of the SENSEI® Laparoscopic Tethered Gamma Probe for 99mTc-nanocolloid Sentinel Lymph Node Biopsy in Prostate Cancer

Role: lead

NCT03731026Phase 3Unknown

The LightPath® and 68Ga-RM2 in Breast Cancer Study

Role: lead

NCT02666079Not ApplicableUnknown

The LightPath® Breast Cancer Study

Role: lead

NCT02446379Withdrawn

Use of the EnLightTM and LightPathTM Imaging Systems in Gastrointestinal Tumour Surgery

Role: lead

NCT02151071Phase 1Unknown

The Breast Surgery EnLight and LightPath Imaging System Study

Role: lead

NCT02037269Completed

LightPathTM Imaging System for Ex-vivo Assessment of Margin and Lymph Node Status in Breast Cancer Surgical Specimens

Role: lead

NCT02151097Completed

PRIME - PRostate Imaging for Margin Evaluation

Role: lead

All 7 trials loaded